Skip to main content
. 2021 Mar 1;37(3):379–385. doi: 10.1007/s12288-020-01372-y

Table 3.

Toxicities to DA-R-EPOCH regimen in this study as compared to the prospective study by Duleavy et al. (6)

Toxicities (Grade 3/4) Dunleavy et al6 (n = 51) Present Study (n = 37)
Hospitalization for FN 13% of cycles

23% of cycles (23/219)

14 (37.8%) patients

Anemia Not reported 9 (24.3%)
Peripheral Neuropathy 8 (15.7%) 7 (18.9%)
Mucositis 4 (7.8%) 4 (10.8%)
Ileus 0 1 (2.7%)
Left ventricular dysfunction 0 1 (2.7%)
AML 1 (1.9%) 0